The researchers that found DC-based vaccination could induce and activate tumor antigen-specific CTLs, whereas WT1 peptide vaccination therapy could not increase WT1-specific CTL numbers in patients with rGB73, which fully demonstrated that DCs play a crucial role in immune regulation and that tumor-specific peptide-pulsed DC vaccination prolongs rGB patient survival. Here, WT1 is linked to neoplasm.